Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)

• Main Authors: Eric L. Simpson (Author), Vimal H. Prajapati (Author), Yael A. Leshem (Author), Raj Chovatiya (Author), Marjolein S. de Bruin-Weller (Author), Sonja Ständer (Author), Andrew E. Pink (Author), Brian M. Calimlim (Author), Wan-Ju Lee (Author), Henrique Teixeira (Author), Barry Ladizinski (Author), Xiaofei Hu (Author), Yang Yang (Author), Yingyi Liu (Author), Meng Liu (Author), Ayman Grada (Author), Andrew M. Platt (Author), Jonathan I. Silverberg (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Atopic dermatitis (AD) is characterized by intense itch and other symptoms that negatively impact quality of life (QoL). This study evaluates the effect of upadacitinib (an oral selective Janus kinase inhibitor) monotherapy on patient-reported outcomes (PROs) among adults and a...